<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513344</url>
  </required_header>
  <id_info>
    <org_study_id>06.38.MET</org_study_id>
    <nct_id>NCT00513344</nct_id>
  </id_info>
  <brief_title>Efficacy of Polyphenols From Milk and Dark Chocolate</brief_title>
  <official_title>Efficacy of Polyphenols From Milk and Dark Chocolate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dark chocolate is one of the richest sources of polyphenols though it has been hypothesised
      that the bioavailability and therefore probably the bioefficacy of epicatechin from milk
      chocolate was reduced compared to dark. This study is designed to compare milk and dark
      chocolate as a source of polyphenols with a control &quot;chocolate&quot; for improving a risk
      biomarker for vascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dark chocolate is one of the richest sources of polyphenols, for example, a standard 40g
      portion of dark chocolate contains 400-800 mg of polyphenols, compared to red wine (170 mg
      /100ml) or an apple (200 mg/piece). Cocoa polyphenols, most notably the catechins, can exist
      in both lipid and water-based environments (amphipathic), meaning they can spare both
      lipophilic and hydrophilic vitamins. There have been a number of human trials conducted using
      chocolate or cocoa and measuring various endpoints. Most have been conducted with dark
      chocolate. An article in Nature found that the bioavailability of epicatechin from milk
      chocolate was substantially reduced compared to dark, and even dark taken with a glass of
      milk (Serafini et al 2003). The hypothesis was that the milk proteins bind to polyphenols,
      making them unavailable. Subsequent studies have not been able to reproduce this, but none
      have been conducted using solid chocolate as the first study, all have been done using a
      drink matrix, which may completely alter the binding interactions of the polyphenols and
      protein. To this end, this study is designed to compare solid chocolates as a source of
      polyphenols for improving a risk biomarker for vascular disease.

      This study is designed as a blinded, three arm crossover trial. The primary outcome measure
      is to compare endothelial function after consumption of 3 chocolates (1 milk, 1 dark, 1
      polyphenol-free control) with a secondary outcome of arterial stiffness. All volunteers will
      take all chocolate types in a crossover design. Subjects will undergo medical screening,
      anthropometry, physical activity and dietary assessments before randomization for the order
      of consumption.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Reactive Hyperemia Index (RHI) From Baseline (20 Min Before Product Intake) to 2 Hours Following Product Intake</measure>
    <time_frame>Baseline and 2 hours</time_frame>
    <description>Value of RHI at 2 hours minus value at baseline. RHI reflects the endothelial function of a vessel at the distal phalanx of a finger, i.e. the capacity of the vessel to dilate after an ischemia. RHI is the increase of blood flow following the occlusion of the brachial artery during 5 minutes by the inflation of an armcuff. RHI was measured by peripheral arterial tonometry using a fingerprobe connected to an EndoPat analyser.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Arterial Stiffness From Baseline (20 Min Before Product Intake) to Two Hours Following Product Intake</measure>
    <time_frame>baseline and 2 hours</time_frame>
    <description>Value of arterial stiffness at 2 hours minus value at baseline. Arterial stiffness is also automatically calculated by peripheral arterial tonometry which consists in measuring the peripheral vessel endothelial response to an ischemia provoked by a 5-min occlusion of the humeral artery using an armcuff.
An increase in arterial stiffness means an increase in the resistance of the vessel wall which reflects an impaired endothelial response to ischemia.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>No Disease</condition>
  <arm_group>
    <arm_group_label>dark chocolate containing polyphenols</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dark chocolate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milk chocolate containing polyphenols</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bespoke milk chocolate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control chocolate with no polyphenols</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cocoa-free chocolate</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dark Chocolate</intervention_name>
    <description>1 portion</description>
    <arm_group_label>dark chocolate containing polyphenols</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Milk Chocolate</intervention_name>
    <description>1 portion</description>
    <arm_group_label>Milk chocolate containing polyphenols</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control (polyphenol-free) &quot;Chocolate&quot;</intervention_name>
    <description>one portion</description>
    <arm_group_label>Control chocolate with no polyphenols</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25- 45 years, male and female

          -  Healthy as determined by the medical questionnaire

          -  Normal weight: BMI 19 - 25

          -  Having given informed consent

        Exclusion Criteria:

          -  Intestinal or metabolic diseases/disorders such as diabetic, renal, hepatic,
             hypertension, pancreatic or ulcer, including lacto-intolerance.

          -  Have had a major gastrointestinal surgery.

          -  Have a regular consumption of medication.

          -  Have an exceptionally high intake of chocolate or similarly high polyphenol foods.

          -  Have a high and regular intake of vitamin supplements

          -  Have an alcohol intake: &gt; 2 units a day

          -  Patient who cannot be expected to comply with treatment.

          -  Smoker

          -  Having a nut allergy

          -  Unwilling to consume chocolate

          -  Currently participating or having participated in another clinical trial during the
             last 3 weeks.

          -  Having given blood in the past three weeks

          -  More than 3 x 45 min of exercise per week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen A Cooper, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nestlé</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Williamson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nestlé</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nestle Research Center</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Heiss C, Finis D, Kleinbongard P, Hoffmann A, Rassaf T, Kelm M, Sies H. Sustained increase in flow-mediated dilation after daily intake of high-flavanol cocoa drink over 1 week. J Cardiovasc Pharmacol. 2007 Feb;49(2):74-80.</citation>
    <PMID>17312446</PMID>
  </reference>
  <reference>
    <citation>Fisher ND, Hollenberg NK. Aging and vascular responses to flavanol-rich cocoa. J Hypertens. 2006 Aug;24(8):1575-80.</citation>
    <PMID>16877960</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>March 28, 2013</results_first_submitted>
  <results_first_submitted_qc>July 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2013</results_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endothelial function</keyword>
  <keyword>Arterial stiffness</keyword>
  <keyword>Dark chocolate</keyword>
  <keyword>Milk chocolate</keyword>
  <keyword>Polyphenols</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>5 healthy subjects, 2 females and 3 males, were recruited within the staff of the Nestlé Research Center in June-July 2008.</recruitment_details>
      <pre_assignment_details>From 3 days before the first test session no foods containing epicatechin or catechin or procyanidins should be ingested. The subjects received a single dose of the 3 products in a randomised order with a minimum of 3 days washout in between (crossover design). The duration of the study was a minimum of 15 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Each Subject Tested the Three Products Randomly Following</title>
          <description>Before the 1st intervention, no food with polyphenols was admitted
Each subject was administered the three products randomly(one product per one-day intervention) according to the six possible sequencies:
Either dark chocolate first, then milk chocolate then control
or dark chocolate first, then control, then milk chocolate
or control first, then dark chocolate, then milk chocolate
or Control first, then milk chocolate, then dark chocolate
or Milk chocolate first, then control, then dark chocolate
or milk chocolate first, then dark chocolate, then control r dark chocolate was given once in the morning (1 day) Products were administered in the morning of the testing day. The testing days (interventions) were separated by a three-day wash-out period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Diet Restriction (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>1st Intervention 1 Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 3 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2nd Intervention 1 Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 3 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>3rd Intervention 1 Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive control first, milk chocolate first, and dark chocolate first</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 28 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>between 28 and 42 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 42 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Reactive Hyperemia Index (RHI) From Baseline (20 Min Before Product Intake) to 2 Hours Following Product Intake</title>
        <description>Value of RHI at 2 hours minus value at baseline. RHI reflects the endothelial function of a vessel at the distal phalanx of a finger, i.e. the capacity of the vessel to dilate after an ischemia. RHI is the increase of blood flow following the occlusion of the brachial artery during 5 minutes by the inflation of an armcuff. RHI was measured by peripheral arterial tonometry using a fingerprobe connected to an EndoPat analyser.</description>
        <time_frame>Baseline and 2 hours</time_frame>
        <population>Taking into account the fact that there is no background data and that we need to have accurate evaluation of central tendency and dispersion, a minimum of five complete subjects are needed.
Data from all randomized subjects were considered in the intention to treat model (for the primary outcome).</population>
        <group_list>
          <group group_id="O1">
            <title>Control Chocolate With no Polyphenols</title>
            <description>cocoa-free chocolate
Control (polyphenol-free)</description>
          </group>
          <group group_id="O2">
            <title>Milk Chocolate Containing Polyphenols</title>
            <description>Bespoke milk chocolate
Milk Chocolate : 1 portion</description>
          </group>
          <group group_id="O3">
            <title>Dark Chocolate Containing Polyphenols</title>
            <description>dark chocolate
Dark Chocolate : 1 portion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Reactive Hyperemia Index (RHI) From Baseline (20 Min Before Product Intake) to 2 Hours Following Product Intake</title>
          <description>Value of RHI at 2 hours minus value at baseline. RHI reflects the endothelial function of a vessel at the distal phalanx of a finger, i.e. the capacity of the vessel to dilate after an ischemia. RHI is the increase of blood flow following the occlusion of the brachial artery during 5 minutes by the inflation of an armcuff. RHI was measured by peripheral arterial tonometry using a fingerprobe connected to an EndoPat analyser.</description>
          <population>Taking into account the fact that there is no background data and that we need to have accurate evaluation of central tendency and dispersion, a minimum of five complete subjects are needed.
Data from all randomized subjects were considered in the intention to treat model (for the primary outcome).</population>
          <units>percentage of the pulse wave amplitude</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="0.52"/>
                    <measurement group_id="O2" value="2.30" spread="0.71"/>
                    <measurement group_id="O3" value="2.26" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Arterial Stiffness From Baseline (20 Min Before Product Intake) to Two Hours Following Product Intake</title>
        <description>Value of arterial stiffness at 2 hours minus value at baseline. Arterial stiffness is also automatically calculated by peripheral arterial tonometry which consists in measuring the peripheral vessel endothelial response to an ischemia provoked by a 5-min occlusion of the humeral artery using an armcuff.
An increase in arterial stiffness means an increase in the resistance of the vessel wall which reflects an impaired endothelial response to ischemia.</description>
        <time_frame>baseline and 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Chocolate With no Polyphenols</title>
            <description>cocoa-free chocolate
Control (polyphenol-free)</description>
          </group>
          <group group_id="O2">
            <title>Milk Chocolate Containing Polyphenols</title>
            <description>Bespoke milk chocolate
Milk Chocolate : 1 portion</description>
          </group>
          <group group_id="O3">
            <title>Dark Chocolate Containing Polyphenols</title>
            <description>dark chocolate
Dark Chocolate : 1 portion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Arterial Stiffness From Baseline (20 Min Before Product Intake) to Two Hours Following Product Intake</title>
          <description>Value of arterial stiffness at 2 hours minus value at baseline. Arterial stiffness is also automatically calculated by peripheral arterial tonometry which consists in measuring the peripheral vessel endothelial response to an ischemia provoked by a 5-min occlusion of the humeral artery using an armcuff.
An increase in arterial stiffness means an increase in the resistance of the vessel wall which reflects an impaired endothelial response to ischemia.</description>
          <units>percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.23" spread="11.16"/>
                    <measurement group_id="O2" value="1.23" spread="12.87"/>
                    <measurement group_id="O3" value="-9.49" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse Events Not Collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Dark Chocolate</title>
        </group>
        <group group_id="E2">
          <title>Milk Chocolate</title>
        </group>
        <group group_id="E3">
          <title>Control</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Maurice Beaumont, Principal Investigator</name_or_title>
      <organization>Clinical Development Unit / Metabolic Unit</organization>
      <phone>+41217858054</phone>
      <email>maurice.beaumont@rdls.nestle.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

